Silver Book Fact

Antibiotic resistance of Klebsiella pneumoniae on the rise

Resistance of Klebsiella pneumoniae to antibiotics has dramatically increased- from 5.3% to 11.6% for third generation cephalosporins (between 1999 and 2010), and from <0.1% to 4.5% for carbapenams (between 2002 and 2010).

Braykov N, Eber M, Klein E, Morgan D, et al. Trends in Resistance to Carbapenems and Third-Generation Cephalasporins Among Clinical Isolates of Klebsiella Pneumoniae in the United States, 1999-2010. Infect Control Hosp Epidemiol. 2013; 34(3): 259-68. https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/div-classtitletrends-in-resistance-to-carbapenems-and-third-generation-cephalosporins-among-clinical-isolates-of-span-classitalicklebsiella-pneumoniaespan-in-the-united-states-19992010div/92079FCA7AE739268B12B1EA67759598

Reference

Title
Trends in Resistance to Carbapenems and Third-Generation Cephalasporins Among Clinical Isolates of Klebsiella Pneumoniae in the United States, 1999-2010
Publication
Infect Control Hosp Epidemiol
Publication Date
2013
Authors
Braykov N, Eber M, Klein E, Morgan D, et al
Volume & Issue
Volume 34, Issue 3
Pages
259-68
URL
Read Full Resource

Categories

  • Cost of Disease
  • Prevalence & Incidence

Related Facts

  • Drug-resistant infections increase length & cost of hospital stays
    Drug-resistant infections increase the length of hospital stays by more than 23% and the cost by close to 30%.  
  • Infection and related sepsis leading cause of death in noncardiac-ICUs
    Infection and related sepsis/septicemia are the leading cause of death in noncardiac-ICUs, accounting for as many as 60% of deaths.  
  • Majority of C. diff deaths in ages 65+
    More than 90% of deaths from C. difficile infectious occur in people ages 65 and older.  
  • Risk of HAIs from hospitalization increases with age
    Hospitalized elderly patients are 2 – 5 times more likely to develop a healthcare-associated infection than younger patients.  
  • Drug resistant infections cost $16.6 – $26 billion to US healthcare system annually
    Drug-resistant infections cost the U.S. healthcare system between $16.6 and $26 billion in extra costs each year.